Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
Resumen
Palabras clave
mCRPC; Cabazitaxel; CAPRISTANA
Citación recomendada
Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, et al. Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. Cancers. 2020 Apr 17;12(4):995.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/6236Este elemento aparece en las siguientes colecciones
- HVH - Articles científics [2952]
- VHIO - Articles científics [860]
El ítem tiene asociados los siguientes ficheros de licencia: